Nebivololo Pensa (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist used primarily in cardiovascular therapy.

• Hypertension: lowers systolic and diastolic blood pressure, reducing risk of stroke and myocardial infarction.
• Chronic heart failure: improves left‑ventricular ejection fraction and decreases hospitalization rates.
• Chronic stable angina: reduces frequency of chest pain episodes by decreasing myocardial oxygen demand.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, diminishing heart rate and contractility. Concurrently, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide‑mediated vasodilation, which lowers peripheral vascular resistance and contributes to overall blood pressure reduction.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness: especially on standing (orthostatic).
• Fatigue: feeling of tiredness or lack of energy.
• Nasal congestion: mild blockage of nasal passages.
• Diarrhea: loose stools, usually transient.
• Bradycardia: heart rate below normal range.

Serious or Rare Side Effects

• Severe bradycardia: may require medical attention.
• Heart block: atrioventricular conduction disturbances.
• Acute heart failure decompensation.
• Bronchospasm: especially in patients with reactive airway disease.
• Hypotension: marked drop in blood pressure causing syncope.
• Liver enzyme elevation: abnormal hepatic function tests.

Before initiating therapy, consider the following safety measures.

• Cardiovascular assessment: evaluate heart rate, blood pressure, and cardiac function.
• Respiratory disease: avoid in uncontrolled asthma or severe COPD.
• Diabetes monitoring: may mask hypoglycaemia symptoms.
• Renal impairment: adjust dose in severe renal dysfunction.
• Drug interactions: review concomitant medications for potential additive effects.
• Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture and light.

Nebivolol may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Combined β‑blockers: additive bradycardia and hypotension.
• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): markedly increase nebivolol plasma levels.
• Calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effect.
• Antidiabetic agents: monitor blood glucose as symptoms of hypoglycaemia may be blunted.
• NSAIDs: can reduce antihypertensive efficacy.
• Antidepressants (tricyclics): may increase risk of cardiac conduction abnormalities.